Switch View
© PR Newswire
06.11.2025
ISIN: US29350E2037
Lunai Bioworks Inc.
LNAI
LISTED
NASDAQ
Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy
News Preview
Lunai Bioworks Announces Publication of Second-Generation Allogeneic Dendritic Cell Therapy Platform in the journal "Vaccines".
LOS ANGELES, Nov. 6, 2025 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, has announced a major scientific breakthroug...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: FR0005175080
Transgene SA
TNG
LISTED
EURONEXT
Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines
News Preview
Computational tool improves recombinant virus design efficiency and yield....
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2025
ISIN: US29350E2037
Lunai Bioworks Inc.
LNAI
LISTED
NASDAQ
Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy
News Preview
Lunai Bioworks Announces Publication of Second-Generation Allogeneic Dendritic Cell Therapy Platform in the journal "Vaccines".
LOS ANGELES, Nov. 6, 2025 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, has announced a major scientific breakthroug...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© EQS Newswire
06.11.2025
ISIN: CH0013396012
SKAN Group AG
SKAN
LISTED
SIX
SKAN will miss sales and profit expectations for 2025 – order intake and backlog are developing very positively and laying a strong foundation for 2026
News Preview
Ad hoc announcement pursuant to Art. 53 LR
SKAN will miss sales and profit expectations for 2025 – order intake and backlog are developing very positively and laying a strong foundation for 2026
Allschwil, November 6, 2025 – The SKAN Group conducted a planned review of its project portfolio in the last days. This assessment identified delays in s......
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© EQS Newswire
06.11.2025
ISIN: CH0013396012
SKAN Group AG
SKAN
LISTED
SIX
SKAN wird Umsatz und Gewinnerwartung 2025 verfehlen – Auftragseingang und -bestand entwickeln sich sehr positiv und legen starke Basis für 2026
News Preview
Ad hoc-Mitteilung gemäss Art. 53 KR
SKAN wird Umsatz und Gewinnerwartung 2025 verfehlen – Auftragseingang und -bestand entwickeln sich sehr positiv und legen starke Basis für 2026
Allschwil, 6. November 2025 – Die SKAN Gruppe hat in den letzten Tagen eine planmässige Überprüfung des Projektportfolios durchgeführt. Dabei wurden zeitliche Verschieb......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.11.2025
ISIN: US60770K1079
Moderna, Inc
MRNA
LISTED
NASDAQ
Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates
News Preview
Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51)Narrows 2025 projected revenue range to $1.6 - $2.0 billionImproves 2025 expected GAAP operating expenses by $0.7 billion to a range of $5.2 - $5.4 billionIncreases 2025 expected year-end cash balance by $0.5 billion - $1 billion to a range of $6.5...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: US08205P1003
Benitec Biopharma, Inc.
BNTC
LISTED
NASDAQ
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering
News Preview
HAYWARD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- directed RNA interference (“ddRNAi”) “Silence and Replace” platform, today announced the pricing of it...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2025
ISIN: KYG0330A1013
Alphamab Oncology
9966
LISTED
HKSE
Alphamab Oncology Showcases Cutting-edge Breakthroughs and Innovative Achievements at the 16th World ADC San Diego
News Preview
SUZHOU, China, Nov. 6, 2025 /PRNewswire/ -- The 16th World ADC San Diego, held from November 3–6, 2025, brought together industry leaders in San Diego, USA. Dr. Ting Xu, Founder, Chairman, and CEO of Alphamab Oncology, was invited to deliver a presentation titled "JSKN021: EGFR/HER3 Targeted Dual-payload ADC", sh...
Themefolio
Profiler
Peergroup
© Newsfile
06.11.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
SVRA DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Savara Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 7 Deadline in Securities Class Action - SVRA
News Preview
New York, New York--(Newsfile Corp. - November 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024 and May 23, 2025, both dates inclusive (the "Class Period"), of the important November 7, 2025 lead plaintiff deadline.SO WHAT: If you purchased Savara...
Themefolio
Profiler
Peergroup
© Newsfile
06.11.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
LANTHEUS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Lantheus Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 10 Deadline in Securities Class Action - LNTH
News Preview
New York, New York--(Newsfile Corp. - November 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between February 26, 2025 and August 5, 2025, both dates inclusive (the "Class Period"), of the important November 10, 2025 lead plaintiff deadline.SO WHAT: If y...
Themefolio
Profiler
Peergroup
© Newsfile
06.11.2025
ISIN: US4718712023
Jasper Therapeutics, Inc.
JSPR
LISTED
NASDAQ
JSPR DEADLINE: ROSEN, A LONGSTANDING FIRM, Encourages Jasper Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 18 Deadline in Securities Class Action - JSPR
News Preview
New York, New York--(Newsfile Corp. - November 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), of the important November 18, 2025 lead plaintiff deadline.SO WHAT: If y...
Themefolio
Profiler
Peergroup
© Newsfile
06.11.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Baxter International Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BAX
News Preview
New York, New York--(Newsfile Corp. - November 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (NYSE: BAX) between February 23, 2022 and July 30, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.SO WHAT: If y...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Newsfile
06.11.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
ROSEN, A LEADING NATIONAL FIRM, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR
News Preview
New York, New York--(Newsfile Corp. - November 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 and September 12, 2025, both dates inclusive (the "Class Period"), of the important December 8, 2025 lead plaintiff deadline.SO WHAT: I...
Themefolio
Profiler
Peergroup
© Newsfile
06.11.2025
ISIN: US05352A1007
Avantor Inc
AVTR
LISTED
NYSE
ROSEN, A TOP RANKED LAW FIRM, Encourages Avantor, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AVTR
News Preview
New York, New York--(Newsfile Corp. - November 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Avantor, Inc. (NYSE: AVTR) between March 5, 2024 and October 28, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has alrea...
Themefolio
Profiler
Peergroup
© Newsfile
06.11.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
ROSEN, A LEADING LAW FIRM, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTX
News Preview
New York, New York--(Newsfile Corp. - November 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.S...
Themefolio
Profiler
Peergroup
© Newsfile
06.11.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important November 17 Deadline in Securities Class Action - CYTK
News Preview
New York, New York--(Newsfile Corp. - November 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the "Class Period"), of the important November 17, 2025 lead plaintiff deadline.SO WHAT: If you pur...
Themefolio
Profiler
Peergroup
© Newsfile
06.11.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Molina Healthcare, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MOH
News Preview
New York, New York--(Newsfile Corp. - November 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Molina Healthcare, Inc. (NYSE: MOH) between February 5, 2025 and July 23, 2025, both dates inclusive (the "Class Period"), of the important December 2, 2025 lead plaintiff deadline.SO WHAT: If yo...
Themefolio
Profiler
Peergroup
© Newsfile
06.11.2025
ISIN: US2521311074
Dexcom Inc
DXCM
LISTED
NASDAQ
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DXCM
News Preview
New York, New York--(Newsfile Corp. - November 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period") of the important December 29, 2025 lead plaintiff deadline.SO WHAT: If you purc...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: IE00BTN1Y115
Medtronic PLC
MDT
LISTED
NYSE
Medtronic to announce financial results for its second quarter of fiscal year 2026
News Preview
GALWAY, Ireland, Nov. 5, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Tuesday, November 18, 2025, for its second quarter of fiscal year 2026, which ended on Friday, October 24, 2025....
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US1404752032
Sonida Senior Living Inc
SNDA
LISTED
NYSE
Sonida Senior Living Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sonida Senior Living, Inc. - SNDA
News Preview
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Sonida Senior Living, Inc. (the “Company”) (NYSE: SNDA) and CNL Healthcare Properties, Inc. Upon closing of the proposed transaction, Sonida existing shareholders’ ownership would range fro...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: US4523271090
Illumina Inc
ILMN
LISTED
NASDAQ
Illumina Responds to Positive Updates from Chinese Ministry of Commerce
News Preview
SAN DIEGO, Nov. 5, 2025 /PRNewswire/ -- The Chinese Ministry of Commerce (MOFCOM) today announced it will lift the export ban on Illumina, Inc. (NASDAQ: ILMN), which had been in place since March 4, 2025. While the ban will be lifted on November 10, Illumina remains on the Unreliable Entities List (UEL), requirin...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US7170811035
Pfizer Inc
PFE
LISTED
NYSE
Pfizer Responds to Delaware Chancery Court Ruling
News Preview
Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court’s decision denying Pfizer’s request for a temporary restraining order to prevent Metsera, Inc. from terminating the existing merger agreement in favor of a competing proposal from Novo Nordisk.
“We remain confident in the merits of our claims a...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: US9216591084
Vanda Pharmaceuticals Inc
VNDA
LISTED
NASDAQ
Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference
News Preview
WASHINGTON, Nov. 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Stifel 2025 Healthcare Conference in New York City on Wednesday, November 12, 2025. A corporate presentation is scheduled for 4:40 p.m. Eastern Time....
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US90337L1089
US Physical Therapy Inc
USPH
LISTED
NYSE
U.S. Physical Therapy Reports Third Quarter 2025 Results
News Preview
U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today reported results for the three and nine months ended September 30, 2025.
FINANCIAL HIGHLIGHTS
Adjusted EBITDA (1), a non-Generally Accepted Accoun...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US4781601046
Johnson & Johnson
JNJ
LISTED
NYSE
Johnson & Johnson to Participate in the Citi’s 2025 Global Healthcare Conference
News Preview
Johnson & Johnson (NYSE: JNJ) will present at the Citi’s 2025 Global Healthcare Conference on Wednesday, December 3rd, 2025. Management will participate in a Fireside Chat at 11:15 a.m. Eastern Time.
A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com....
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US71742Q1067
Phibro Animal Health Corp
PAHC
LISTED
NASDAQ
Phibro Animal Health Corporation Reports First Quarter Results, Updates Financial Guidance
News Preview
Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its first quarter ended September 30, 2025 and its updated financial guidance for the year ending June 30, 2026.
Highlights for the three months ended September 30, 2025 (compared to the three months ended September 30, 2024)
Net sa...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17
News Preview
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual healthcare services and pharmacy, today announced that the Company has rescheduled its third quarter 2025 earnings release and conference call to Monday, November 17, 2025. The Company expects to file a Form 12b-25, as needed, notifying the U.S....
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US46266C1053
IQVIA Holdings Inc
IQV
LISTED
NYSE
Dr. William G. Kaelin Jr. joins IQVIA Board of Directors
News Preview
IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced the appointment of Dr. William G. Kaelin Jr. to its board of directors, effective today.
Dr. Kaelin is a Senior Physician-Scientist at Brigham and Women’s Hospital in Boston and the Sidney Farber Professor of Medic...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US29332G1022
Enhabit Inc
EHAB
LISTED
NYSE
Enhabit Reports Third Quarter 2025 Financial Results
News Preview
Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice care provider, today reported its results of operations for the third quarter ended Sept. 30, 2025.
“Our third quarter results reflect strong execution on our core strategic priorities, with year-over-year growth in revenue, census and Adjusted EBITDA,” said Barb Jacobsmeyer, president...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US58155Q1031
McKesson Corp
MCK
LISTED
NYSE
McKesson Corporation Reports Fiscal 2026 Second Quarter Results and Raises Full Year Adjusted EPS Guidance
News Preview
McKesson Corporation (NYSE: MCK) has released its fiscal 2026 second quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results.
As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, Novemb...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: US0043971052
Accuray Inc
ARAY
LISTED
NASDAQ
Accuray Reports Fiscal 2026 First Quarter Financial Results
News Preview
MADISON, Wis., Nov. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter ended September 30, 2025....
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: US00444T2096
Talphera Inc
TLPH
LISTED
NASDAQ
Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025
News Preview
SAN MATEO, Calif., Nov. 5, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2025 financial resul...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: IE00B4Q5ZN47
Jazz Pharmaceuticals PLC
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
News Preview
– Modeyso™ approved as the first and only treatment for recurrent H3 K27M-mutant DMG –
– Zepzelca® and atezolizumab (Tecentriq®) combination approved as maintenance therapy in 1L ES-SCLC –
– 3Q25 total revenues increased 7% year-over-year driven by robust growth of Epidiolex®, Xywav® and the launch o...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: US70975L1070
Penumbra Inc
PEN
LISTED
NYSE
Penumbra, Inc. Reports Third Quarter 2025 Financial Results
News Preview
ALAMEDA, Calif., Nov. 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2025....
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: US2197981051
QuidelOrtho Corp
QDEL
LISTED
NASDAQ
QuidelOrtho Reports Third Quarter 2025 Financial Results
News Preview
―
Total revenue of $700 million; excluding COVID-19 and Donor Screening, revenue grew mid-single digits, demonstrating solid underlying growth and momentum ―
― Successful completion of debt refinancing, enhancing financial flexibility through...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US87650L1035
Tarsus Pharmaceuticals Inc
TARS
LISTED
NASDAQ
Tarsus to Participate in Upcoming Investor Conference
News Preview
IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, MA on Tuesday, November 11th, at 11:30 a.m. PT / 2:30 p.m. ET....
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US92764N1028
Vir Biotechnology Inc
VIR
LISTED
NASDAQ
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the third quarter ended September 30, 2025.
"Our third quarter demonstrated exceptional execution across our clinical portfolio," said Marianne De Backer, Chief Executive Officer, Vir Biotechnology. "We completed ECLIPSE 1 enrollment approx...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US0042251084
ACADIA Pharmaceuticals Inc
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2025.
“Acadia delivered another strong quarter, generating total revenue of $278.6 million,” said Catherine Owen Adams, Chief Executive Officer. “NUPLAZID achieved record sales of $177.5 million representing a significant inf...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US30052C1071
Evolus Inc
EOLS
LISTED
NASDAQ
Evolus Reports Third Quarter 2025 Financial Results
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the third quarter ended September 30, 2025.
“Our third quarter results reflect double-digit growth despite the current market environment. Our continued above market performance an...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US40131M1099
Guardant Health Inc
GH
LISTED
NASDAQ
Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based screening test demonstrates patient adherence of 95% in screening for colorectal cancer (CRC). Shield is the first and only blood test to receive FDA app...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US80810D1037
Schrodinger Inc
SDGR
LISTED
NASDAQ
Schrödinger Reports Third Quarter 2025 Financial Results
News Preview
Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the quarter ended September 30, 2025.
"Schrödinger delivered a solid third quarter with software revenue growth of 28%, reflecting the industry’s increasing demand for our leading computational platform,” said Ramy Farid, Ph.D., chief executive officer of Schrödinger. “While w...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US45781M1018
Innoviva Inc
INVA
LISTED
NASDAQ
Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress
News Preview
Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter e...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US2074101013
Conmed Corp
CNMD
LISTED
NYSE
CONMED Corporation Announces Third Quarter 2025 Financial Results
News Preview
CONMED Corporation (NYSE: CNMD) today announced financial results for the third quarter ended September 30, 2025.
Third Quarter 2025 Highlights
Sales of $337.9 million increased 6.7% year-over-year as reported and 6.3% in constant currency.
Domestic revenue increased 5.9% year-over-year.
International revenue increased 7.8% year-over-year...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US00404A1097
Acadia Healthcare Company Inc
ACHC
LISTED
NASDAQ
Acadia Healthcare Reports Third Quarter 2025 Results
News Preview
Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) (NASDAQ: ACHC) today announced financial results for the third quarter ended September 30, 2025.
Third Quarter 2025 Results
Revenue totaled $851.6 million, an increase of 4.4% over the third quarter of 2024
Same facility revenue increased 3.7% compared with the third quarter of 2024,...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US74587B1017
Pulse Biosciences Inc
PLSE
LISTED
NASDAQ
Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results
News Preview
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the third quarter ended September 30, 2025.
Recent Business Highlights
Soft Tissue Ablation
Initiated a m...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US0906831039
Biote Corp
BTMD
LISTED
NASDAQ
Biote Reports Third Quarter 2025 Financial Results
News Preview
Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners’ patients, today announced financial results for the third quarter ended September 30, 2025.
“When we undertook our organizational restructuring in May, we identified three strategic priorities: accelerate...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US74765K1051
Quantum-Si Inc
QSI
LISTED
NASDAQ
Quantum-Si Reports Third Quarter 2025 Financial Results
News Preview
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced financial results for the third quarter ended September 30, 2025.
Press Release Highlights
Reported revenue of $552,000 for the third quarter of 2025
An...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: US2681582019
Dynavax Technologies Corp
DVAX
LISTED
NASDAQ
Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program
News Preview
HEPLISAV-B® quarterly net product revenue of $90 million, a 13% YoY increase; r
eiterates full year 2025 HEPLISAV-B® net product revenue guidance range of $315 to $325 million
Board of Directors authorizes new $100...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: CA23126M1023
Curaleaf Holdings Inc
CURA
LISTED
TSX
Curaleaf Reports Third Quarter 2025 Results: Solid Growth and Robust Cash Generation
News Preview
Third quarter 2025 net revenue of $320 million
Third quarter 2025 International revenue of $46 million
Third quarter 2025 adjusted gross profit margin(1) of 50%...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: CA23126M1023
Curaleaf Holdings Inc
CURA
LISTED
TSX
Curaleaf Reports Third Quarter 2025 Results: Solid Growth and Robust Cash Generation
News Preview
Third quarter 2025 net revenue of $320 million
Third quarter 2025 International revenue of $46 million
Third quarter 2025 adjusted gross profit margin(1) of 50%...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US0070021086
Adicet Bio Inc
ACET
LISTED
NASDAQ
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2025.
“We were pleased to announce positive preliminary data last month...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US8523123052
STAAR Surgical Co
STAA
LISTED
NASDAQ
STAAR Surgical Reports Third Quarter 2025 Results
News Preview
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the third quarter ended September 26, 2025.
Third Quarter 2025 Financial Overview
Net sales of $94.7 million up 6.9% Y/Y
Net sales included $25.9 million relat...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US86150R1077
Stoke Therapeutics Inc
STOK
LISTED
NASDAQ
Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
News Preview
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chie...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US64135M1053
Neurogene Inc
NGNE
LISTED
NASDAQ
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 1,185 shares of t...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US98401F1057
Xencor Inc
XNCR
LISTED
NASDAQ
Xencor Reports Third Quarter 2025 Financial Results
News Preview
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2025 and provided recent business and clinical program updates.
“Xencor’s two novel, first-in-class, CD3 T-cell enga...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US38341P1021
Gossamer Bio Inc
GOSS
LISTED
NASDAQ
Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
News Preview
Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the third quarter end...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: US2681582019
Dynavax Technologies Corp
DVAX
LISTED
NASDAQ
Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program
News Preview
Collaboration positioned to leverage Vaxart's oral vaccine platform and Dynavax's commercial experience to address the long-term need for easily administered COVID-19 vaccine options
Vaxart to continue leading and funding development...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US98160J1088
MariMed Inc.
MRMD
LISTED
CSE
MariMed Reports Third Quarter 2025 Earnings
News Preview
MariMed reports third quarter 2025 financial results...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US03940C1009
Arcellx Inc
ACLX
LISTED
NASDAQ
Arcellx Provides Third Quarter 2025 Financial Results
News Preview
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported financial results for the third quarter ended September 30, 2025.
Third Quarter 2025 Financial Highlights
Cash, cash equivalents, and marketable...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
EXTENDED CLASS PERIOD: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Lantheus Holdings, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit - LNTH
News Preview
SAN DIEGO, Nov. 5, 2025 /PRNewswire/ --Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Lantheus Holdings, Inc. (NASDAQ: LNTH) common stock between November 6, 2024 and August 6, 2025, inclusive (the "Class Period"). Captioned Indiana Publi...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
